HSP90 inhibition overcomes resistance to molecular targeted therapy in BRAFV600E mutant high-grade glioma. Sasame J, Ikegaya N, Kawazu M, Natsumeda M, et al. Clin Cancer Res 2022 Mar 28. pii: 694027. doi: 10.1158/1078-0432.CCR-21-3622.

Read + Share

Amedeo Smart

Independent Medical Education

Sasame J, Ikegaya N, Kawazu M, Natsumeda M, et al. HSP90 inhibition overcomes resistance to molecular targeted therapy in BRAFV600E mutant high-grade glioma. Clin Cancer Res 2022 Mar 28. pii: 694027. doi: 10.1158/1078-0432.CCR-21-3622.
PMID: 35344043